CEACAM7
Cell adhesion molecule CEACAM7
Also known as: CEA, CEAM7_HUMAN, CGM2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q14002
- Gene
- CEACAM7
- Ensembl
- ENSG00000007306
- Chromosome
- 19
- Canonical length
- 265 aa
- Protein class
- Predicted membrane proteins
- Subcellular location
- Plasma membrane,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a cell surface glycoprotein and member of the carcinoembryonic antigen (CEA) family of proteins. Expression of this gene may be downregulated in colon and rectal cancer. Additionally, lower expression levels of this gene may be predictive of rectal cancer recurrence. This gene is present in a CEA family gene cluster on chromosome 19. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2015]
Canonical amino-acid sequenceUniProt
265 residues, UniProt reviewed canonical sequence.
>Q14002|CEACAM7
1 MGSPSACPYR VCIPWQGLLL TASLLTFWNL PNSAQTNIDV VPFNVAEGKE VLLVVHNESQ
61 NLYGYNWYKG ERVHANYRII GYVKNISQEN APGPAHNGRE TIYPNGTLLI QNVTHNDAGI
121 YTLHVIKENL VNEEVTRQFY VFSEPPKPSI TSNNFNPVEN KDIVVLTCQP ETQNTTYLWW
181 VNNQSLLVSP RLLLSTDNRT LVLLSATKND IGPYECEIQN PVGASRSDPV TLNVRYESVQ
241 ASSPDLSAGT AVSIMIGVLA GMALILocalizationUniProt · AlphaFold · HPA
Whether an antibody against CEACAM7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.39
- Highest tissue expression
- 613 nTPM
Expression across tissuesHPA
Tissue
- rectum: 613 nTPM
- colon: 559 nTPM
- appendix: 68 nTPM
- esophagus: 49 nTPM
- gallbladder: 37 nTPM
- vagina: 34 nTPM
Single-cell type
- colonocytes: 169 nCPM
- esophageal apical cells: 99 nCPM
- pancreatic duct cells: 13 nCPM
- respiratory deuterosomal cells: 5.2 nCPM
- early spermatids: 3.9 nCPM
- ocular epithelial cells: 3.2 nCPM
Immune cell
- neutrophil: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.53
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.64
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CEACAM7 as an antibody target. Whether an autoantibody or antibody against CEACAM7 could matter depends on whether native CEACAM7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CEACAM7 is annotated at the cell surface, where native CEACAM7 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CEACAM7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...